立体定向放射外科治疗脉络丛肿瘤:国际放射外科研究基金会报告
这项多中心研究评估了伽玛刀立体定向放射外科(GKSRS)作为WHO I-III级脉络丛肿瘤(CPT)原发或辅助治疗的作用。共纳入32例患者(20例女性)的43个治疗肿瘤,25例(78%)曾接受初始手术切除,中位肿瘤总体积2.2 cc,中位边缘剂量和最大剂量分别为13 Gy和25.5 Gy。
要点
- GKSRS可作为影像学定义或手术后复发的低级别和高级别CPT的微创替代治疗。
- 6例患者出现远处颅内播散,中位时间22个月;3例(9%)出现持续症状性放射不良反应。
核心结论
- GKSRS是影像学定义或手术后复发的低级别和高级别脉络丛肿瘤的微创替代治疗策略。
研究设计与样本
- 多中心项目分析32例患者(20例女性)共43个治疗肿瘤,25例(78%)曾接受初始手术切除。
- 中位肿瘤总体积2.2 cc,中位边缘剂量13 Gy,中位最大剂量25.5 Gy。
主要发现
- 局部肿瘤控制率为69%。
- 低级别肿瘤1年、3年、5年局部无进展生存率分别为90%、77%、58%。
- 高级别肿瘤1年、3年、5年局部无进展生存率分别为77%、62%、62%。
- 6例患者出现远处颅内播散,中位时间22个月;1年、2年、5年、10年远处脑肿瘤无进展生存率分别为93%、88%、78%、65%。
关键数值与推荐
- 低级别肿瘤1、3、5年局部无进展生存率分别为90%、77%、58%。
- 高级别肿瘤1、3、5年局部无进展生存率分别为77%、62%、62%。
- 远处脑肿瘤1、2、5、10年无进展生存率分别为93%、88%、78%、65%。
- 持续症状性放射不良反应发生率9%(3例)。
临床怎么用
- 对于影像学定义或手术后复发的WHO I-III级脉络丛肿瘤,可考虑GKSRS作为微创治疗选择。
- 治疗时需关注远处颅内播散风险,中位发生时间22个月。
- 需监测持续症状性放射不良反应,中位发生时间11个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Choroid plexus tumors (CPT) are rare epithelial tumors of the choroid plexus. Gross total resection (GTR) may be curative, but it is not always possible. OBJECTIVE: To evaluate the role of Gamma Knife stereotactic radiosurgery (GKSRS) as either a primary or adjuvant management option for WHO grade I-III CPT through a multicenter project. METHODS: A total of 32 patients (20 females) with a total of 43 treated tumors were included in the analysis. A total of 25 patients (78%) had undergone initial surgical resection. The median total tumor volume was 2.2 cc, and the median margin and maximum doses were 13 and 25.5 Gy, respectively. RESULTS: Local tumor control was achieved in 69% of cases. Local tumor progression-free survival (PFS) rate for low-grade tumors at 1, 3, and 5 yr was 90%, 77%, 58%, respectively. The actuarial local tumor PFS rate for high-grade tumors at 1, 3, and 5 yr was 77%, 62%, and 62%, respectively. There was no significant difference in local tumor control rates between low- and high-grade CPT (P = .3). Gender, age, and degree of resection were not associated with treated tumor PFS. Distant intracranial spread developed in 6 patients at a median of 22 mo after initial SRS. Actuarial distant brain tumor PFS rate at 1, 2, 5, and 10 yr was 93%, 88%, 78%, and 65%, respectively. Three patients (9%) developed persistent symptomatic adverse radiation effects at a median of 11 mo after the procedure. CONCLUSION: GKSRS represents a minimally invasive alternative management strategy for imaging defined or surgically recurrent low- and high-grade CPT.
引用
- Faramand A, Kano H, Niranjan A, et al. Stereotactic Radiosurgery for Choroid Plexus Tumors: A Report of the International Radiosurgery Research Foundation. Neurosurgery. 2021. PMID: 33372216. doi:10.1093/neuros/nyaa538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。